March 24, 2026 -- RyboDyn, Inc., a biotechnology company decoding the dark proteome using an AI-powered novel sequencing and discovery platform, today announced the initial close of a $10M Seed financing from a syndicate of new and existing investors. The financing will accelerate the company's transition from foundational discovery into scaled platform execution and progress early-stage programs into IND-enabling studies. RyboDyn founders Imad Ajjawi, PhD (left), and Corey Dambacher, PhD (righ

March 24, 2026 -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with RA Capital Management for a private placement that is expected to result in gross proceeds of approximately $30 million before deducting placement agent fees and offering expenses, and an additional approximately $44 million of gross proceeds if the accompanying warrants are exerci

New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise Fuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population with a Predicted 10-Year CAGR of 7.7% Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the expansion of its cell transplant pipeline wi

PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations. Safety and tolerability findings included: No serious adverse events (0%) No dose-limiting toxicities observed. No treatment discontinuations due to adverse events Day 42 Data Show Higher AUC, Cavg, and Cmax vs Day 1, with ~2.1x Accumulation Supporting Sustained Drug Exposure, Consistent Tolerability, and Clinically Meaningful Response March 24, 2026

March 24, 2026 -- Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has entered a multi-year research collaboration agreement with Merck, known as MSD outside the US and Canada, to discover novel drug targets in inflammatory bowel disease (IBD) using Quotient’s somatic genomics platform technology. Somatic genetic mutations naturally accumulate over a lifetime, resulting in trillions of different genomes within an individual.

March 24, 2026 -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. They also stated that "no saf

-- Additional data from RSV re-vaccination trial demonstrates trend of approximately 60-80% higher RSV neutralizing antibodies (nAbs) for Clover's RSV vaccine compared head-to-head versus AREXVY (GSK) in older adults who previously received an initial dose of AREXVY -- -- Re-vaccination with Clover's RSV vaccine boosted RSV nAbs to approximately 120-135% of the peak levels observed after an initial dose of AREXVY (cross-trial comparison) -- -- Results further strengthen profile of potential best

Kalohexis' lead programs include 710GO, an oral dual melanocortin-3 and-4 receptor (MC3R/MC4R) agonist, a next-generation general obesity treatment; and mifomelatide, a dual MC3R/MC4R antagonist to prevent and treat cachexia in advanced cancers 710GO has shown healthier, more durable weight loss without lean body mass loss and other side effects common with GLP-1 receptor agonists March 19, 2026 -- Endevica Bio, a privately-held company developing first-in-class synthetic peptidomimetics, toda

Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026. Taldefgrobep is a novel inhibitor of the myostatin-activin signaling pathway, which directly targets both fat and muscle, offering the potential to achieve high-quality weight loss in people living with overweight and obesity. In previous clinical studies, taldefgrobep produced meaningful reductions in fat mass while increasin

The new alliance has launched a multi-agent AI framework to support faster, data-driven decisions in cancer research. Agentic AI system achieves 15x faster insights with over 90% accuracy. March 19, 2026--Globant (NYSE: GLOB), a digitally native company that helps organizations thrive in a digital and AI-powered future, and PharmaMar, world leader in the discovery, development and commercialization of marine-derived anti-cancer drugs, today announced a new collaboration designed to speed up can